FIELD: medicine.
SUBSTANCE: invention refers to a lyophilised DNA compound to be applied for treating an ischemic disease and to a method of treating an ischemic disease in an individual. The lyophilised DNA compound contains plasmid DNA, salt and carbohydrate wherein said plasmid DNA contains HGF gene, or its version, and wherein said HGF gene, or its version is specified in a group consisting of flHGF, dHGF, NK1, NK2, NK4 or their mixture. The method of treating an ischemic disease in a human or a mammal involves the introduction of a composition recovered from the lyophilised DNA compound by direct injection.
EFFECT: invention enables effective treatment of the ischemic disease in the human or the mammal.
14 cl, 5 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF NEUROPATHY WITH DNA STRUCTURES ENCODING IGF-1 AND DNA STRUCTURES ENCODING HGF | 2019 |
|
RU2781980C2 |
| LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR NAKED DNA GENE THERAPY | 2019 |
|
RU2795471C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| MODIFIED MITOCHONDRIA AND THEIR USE | 2019 |
|
RU2811467C2 |
| COMPOSITION FOR RELIEVING OR TREATING PAIN | 2017 |
|
RU2725830C1 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| NEW O-SUCCINYL HOMOSERINE TRANSFERASE VARIANT AND METHOD FOR SYNTHESIS OF O-SUCCINYL HOMOSERINE USING SAID VARIANT | 2018 |
|
RU2747493C1 |
| NEW O-SUCCINYL HOMOSERINE TRANSFERASE MUTANT AND METHOD FOR SYNTHESIS OF O-SUCCINYL HOMOSERINE USING SAID MUTANT | 2018 |
|
RU2747494C1 |
| MICROORGANISMS PRODUCING L-VALINE, AND METHOD OF PRODUCING L-VALINE USING SAME | 2021 |
|
RU2822660C1 |
| ANTI-HUMAN ANGIOPOIETIN-LIKE 4 PROTEIN ANTIBODIES | 2010 |
|
RU2580045C2 |
